Total | Early tracheotomy | Late tracheotomy | |
---|---|---|---|
(n = 150) | (n = 72) | (n = 78) | |
Age, years | 64.6 (11.4) | 64.3 (12.4) | 64.9 (10.5) |
65.5 (58;74) | 65 (57.5;74.5) | 65.5 (59;73) | |
n = 150 | n = 72 | n = 78 | |
Male sex | 118 (78.7%) | 57 (79.2%) | 61 (78.2%) |
Female sex | 32 (21.3%) | 15 (20.8%) | 17 (21.8%) |
Body-mass index, kg/m2 | 33.4 (19.5) | 31.3 (6.3) | 35.2 (26.2) |
30.6 (27.2;34.5) | 30.7 (27.3;33.8) | 30.8 (27.1;35.5) | |
n = 146 | n = 69 | n = 77 | |
SAPS3* | 50.8 (8.0) | 51.2 (8.8) | 50.5 (7.2) |
50 (45;55) | 50 (45;57) | 50 (46;55) | |
n = 147 | n = 70 | n = 77 | |
Covid-19 medication | |||
No | 134 (90.5%) | 66 (91.7%) | 68 (89.5%) |
Remdesivir | 11 (7.4%) | 4 (5.6%) | 7 (9.2%) |
Tocilizumab | 3 (2.0%) | 2 (2.8%) | 1 (1.3%) |
Coexisting illness | |||
Heart disease† | 34 (22.7%) | 16 (22.2%) | 18 (23.1%) |
Hypertension | 85 (56.7%) | 36 (50.0%) | 49 (62.8%) |
Asthma | 26 (17.6%) | 13 (18.3%) | 13 (16.9%) |
Chronic obstructive pulmonary disease | 8 (5.3%) | 4 (5.6%) | 4 (5.1%) |
Obstructive sleep apnoea syndrome | 12 (8.0%) | 5 (6.9%) | 7 (9.0%) |
Diabetes | 46 (30.7%) | 19 (26.4%) | 27 (34.6%) |